MedTrace Logo

Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease

NCT07644117 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-06-12

No results posted yet for this study

Summary

This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy.

Participants who have not previously received anti-TNF treatment and are about to start advanced therapy will provide a blood sample to test for the genetic markers. Participants will also undergo regular assessments of current treatment, disease activity, and inflammatory markers during follow-up.

Conditions

  • IBD (Inflammatory Bowel Disease)
  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)

Interventions

OTHER

This is an observational study with no intervention. Patients will receive anti- TNF therapy as part of their standard care

Patients will receive therapy as part of their standard care according to the standard dose

Sponsors & Collaborators

  • Shmuel Kivity, MD

    lead OTHER_GOV

Principal Investigators

  • Ayal Hirsch, MD · Tel Aviv Sourasky University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-04
Primary Completion
2028-05-31
Completion
2028-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07644117 on ClinicalTrials.gov